Navigation Links
Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development

ANN ARBOR, Mich., Feb. 27, 2011 /PRNewswire/ -- With deep regret, Adeona Pharmaceuticals, Inc. (Amex: AEN), announced today the passing of its Senior Vice President of Research & Development, David A. Newsome, M.D. Dr. Newsome invented and developed ZincMonoCysteine and was the first person to pioneer and demonstrate the benefits of oral high dose zinc therapy in age-related macular degeneration, the leading cause of blindness in older Americans. Oral high dose zinc containing nutritional products now represent the standard of care for age-related macular degeneration which affects over 10 million Americans.

During his career, Dr. Newsome spent over a decade in clinical and laboratory research at the National Eye Institute, becoming the Head of the Retinal Disease Section. As Associate Professor at the Johns Hopkins Wilmer Eye Institute, Dr. Newsome combined teaching and clinical work with his laboratory research. Dr. Newsome continued his passion of teaching, patient care, clinical and laboratory research as a full tenured Professor at Louisiana State University Medical School, New Orleans. After teaching there, Dr. Newsome formed his own surgical and medical retina disease private practice, and continued to perform clinical and laboratory research sponsored by the National Institutes of Health and private foundation grants. After the devastation of Hurricane Katrina in New Orleans, Dr. Newsome worked as a surgical ophthalmologist until joining the management team at Adeona in 2006. He earned an M.D. from Columbia University and a B.A. from Duke University, and completed an ophthalmology residency and a fellowship in retinal diseases and surgery at Harvard University. He also completed a retinal fellowship at the Bascom Palmer Eye Institute, University of Miami.

"On behalf of the Board of Directors and all of his colleagues at Adeona, I would like to extend our heartfelt condolences to David's family," stated James S. Kuo, M.D., M.B.A., Adeona's Chairman and CEO. "David was a dear friend and cherished colleague. He will be remembered for his life's work to develop zinc-based therapies for patients. David will be greatly missed."

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical studies and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, the availability of financial and other resources and the allocation of resources among different potential uses, a failure of our clinical trials to be completed on time or to achieve desired results, a failure of the new branding to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeonas Alzheimers Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurologys 63rd Annual Meeting
2. Adeona to Raise $4 Million in Registered Direct Offering
3. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
4. Adeona to Present at OneMedForum San Francisco 2011 Conference
5. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
6. Adeona Announces Third Quarter 2010 Financial Results and Achievements
7. Adeona to Hold Annual Shareholder Meeting
8. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
9. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
10. Adeona Announces Second Quarter 2010 Profitability and Achievements
11. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology:
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ ... in utilization of hospital and nonhospital care, according to a recent study by the ... Louisiana, 16th Edition , found medical payments per claim with more than seven days ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
Breaking Medicine News(10 mins):